Wei Yue, Ph.D.

---

Summary

My research program focuses on studying novel mechanisms involved in regulation of OATP1B1 and OATP1B3 transport function. The long-term goal of my laboratory is to establish a mechanistic model to predict OATP-mediated drug-drug interactions, toxicities and inter-individual variability in drug response. Multi-disciplinary approaches are utilized including: 1) Sandwich-cultured primary human hepatocytes model; 2) Physiologically based pharmacokinetic (PBPK) modeling approach to assess clinically relevant DDIs; 3) Pharmacogenomics studies of drug transport proteins; 4) Post-translational regulation of OATP transporters; 5) Confocal microscopy to study trafficking of the transport proteins.

---

Education & Experience

---

Publications & Presentations

1. Farasyn T, Pahwa S, Xu C, Yue W. Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes. European Journal of Pharmaceutical Sciences. 2021; 165 : 105951

2. Farasyn T, Xu C, Yue W. Development of a primary rat sandwich-cultured hepatocytes model expressing functional human organic anion transporting polypeptide (OATP) 1B3: a novel tool to assess hepatobiliary disposition of human OATP1B3 substrates. Journal of Pharmacy and Pharmaceutical Sciences. In Press; 24 : 475-483

3. Kayesh R, Farasyn T, Crowe A, Liu Q, Pahwa S, Alam K, Neuhoff S, Hatley O, Ding K, Yue W. Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib by applying the total IC50 approach in R-value and physiologically-based pharmacokinetic models. Clinical Pharmacology & Therapeutics. 2021; 109 : ITCW-007

4. Kayesh R, Farasyn T, Crowe A, Liu Q, Pahwa S, Alam K, Neuhoff S, Hatley O, Ding K, Yue W. Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models. Journal of pharmaceutical sciences. 2021; 110 : 314-324

5. Crowe A, Yue W. An integrative method to semi-quantitatively determine membrane transporter expression by immunohistochemistry staining. Bio-Protocol. 2019

Grants

1. Post-translational regulation of hepatic transporters organic anion transporting polypeptide (OATP) 1B1 and 1B3 by immunosuppressant cyclosporine A: Implication in Transporter-Mediated Drug-Drug Interactions. Misc Non-Federal. Start Date: 2018. End Date: 2019.

2. Elucidating novel mechanism underlying OATP1B1/1B3-mediated drug-drug interactions . Misc Non-Federal. Start Date: 2019. End Date: 2019.

3. Post-translational regulation of transporters organic anion transporting polypeptides (OATP) 1B1 and 1B3 by immunosuppressant cyclosporine A: Implication in Transporter-Mediated Drug-Drug Interactions . Misc Non-Federal. Start Date: 2017. End Date: 2018.

4. Administrative amendment of adding human subject research component to current funded R01. NIH. Start Date: 2017. End Date: 2017.

5. Administrative Supplement for Equipment . NIH. Start Date: 2015. End Date: 2017.

Awards and Honors

1. Shandong University, China. Sunshine scholarship. Date: 1996.

Education

1. Degree: Postdoctoral training. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Date: 2008.


2. Degree: Postdoctoral Training. Lineberger Comprehensive Cancer Center, Univeristy of North Carolina at Chapel Hill. Date: 2007.


3. Degree: Ph D. Peking Union Medical College and Shandong University, China. Date: 2001.


4. Degree: MS. Shandong University, China. Date: 1998.


5. Degree: BS. Shandong Agricultural University, China. Date: 1995.